EP1605935A4 - Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central - Google Patents
Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux centralInfo
- Publication number
- EP1605935A4 EP1605935A4 EP04717992A EP04717992A EP1605935A4 EP 1605935 A4 EP1605935 A4 EP 1605935A4 EP 04717992 A EP04717992 A EP 04717992A EP 04717992 A EP04717992 A EP 04717992A EP 1605935 A4 EP1605935 A4 EP 1605935A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- disorders
- compositions
- management
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45237403P | 2003-03-06 | 2003-03-06 | |
US452374P | 2003-03-06 | ||
PCT/US2004/006782 WO2004080393A2 (fr) | 2003-03-06 | 2004-03-05 | Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1605935A2 EP1605935A2 (fr) | 2005-12-21 |
EP1605935A4 true EP1605935A4 (fr) | 2009-05-20 |
Family
ID=32990646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04717992A Withdrawn EP1605935A4 (fr) | 2003-03-06 | 2004-03-05 | Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1605935A4 (fr) |
JP (1) | JP2006519875A (fr) |
KR (1) | KR100831545B1 (fr) |
CN (1) | CN1780616B (fr) |
AU (1) | AU2004220607B2 (fr) |
BR (1) | BRPI0408113A (fr) |
CA (1) | CA2517845A1 (fr) |
IL (1) | IL170710A0 (fr) |
MX (1) | MXPA05009435A (fr) |
NZ (1) | NZ542408A (fr) |
WO (1) | WO2004080393A2 (fr) |
ZA (1) | ZA200507322B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
CA2789014C (fr) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Procedes et compositions pour ameliorer la fonction cognitive |
WO2014078568A1 (fr) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Méthodes et compositions pour le traitement de la schizophrénie |
EP3827820A1 (fr) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam pour améliorer la fonction cognitive |
US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
RU2763425C2 (ru) * | 2017-10-18 | 2021-12-29 | Интрабио Лимитед | Терапевтические агенты для нейродегенеративных заболеваний |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
JP2023549174A (ja) * | 2020-11-04 | 2023-11-22 | グリアセルテック・インコーポレイテッド | クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001348A2 (fr) * | 1993-07-02 | 1995-01-12 | Celgene Corporation | Inhibiteurs du tnf alpha |
WO1997008143A1 (fr) * | 1995-08-29 | 1997-03-06 | Celgene Corporation | Inhibiteurs du facteur de necrose des tumeurs alpha |
WO1999006041A1 (fr) * | 1997-07-31 | 1999-02-11 | Celgene Corporation | ACIDES ALCANOHYDROXAMIQUES SUBSTITUES ET PROCEDE PERMETTANT DE REDUIRE LE NIVEAU DE TNF-$g(a) |
WO2001034606A1 (fr) * | 1999-11-12 | 2001-05-17 | Celgene Corporation | Derives d'isoindoline actifs d'un point de vue pharmaceutique |
WO2001049321A1 (fr) * | 1999-12-31 | 2001-07-12 | Tobinick Edward L | Inhibiteurs du tnf destines au traitement de troubles neurologiques, retiniens et musculaires |
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
WO2003080048A1 (fr) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: leurs procedes d'utilisation et leurs compositions |
WO2005094218A2 (fr) * | 2004-03-05 | 2005-10-13 | Celgene Corporation | Procedes d'utilisation et compositions comprenant des medicaments selectifs inhibiteurs de cytokine pour le traitement et la gestion de troubles du systeme nerveux central |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
AR003951A1 (es) * | 1995-05-26 | 1998-09-30 | Pfizer | Formulacion farmaceutica sinergica para el tratamiento de la enfermedad de parkinson y composiciones para prepararla. |
JP3568749B2 (ja) * | 1996-12-17 | 2004-09-22 | 株式会社デンソー | 半導体のドライエッチング方法 |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
AU2003262187A1 (en) * | 2002-04-12 | 2003-10-27 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
-
2004
- 2004-03-05 KR KR1020057016598A patent/KR100831545B1/ko not_active IP Right Cessation
- 2004-03-05 EP EP04717992A patent/EP1605935A4/fr not_active Withdrawn
- 2004-03-05 MX MXPA05009435A patent/MXPA05009435A/es not_active Application Discontinuation
- 2004-03-05 WO PCT/US2004/006782 patent/WO2004080393A2/fr active Application Filing
- 2004-03-05 CA CA002517845A patent/CA2517845A1/fr not_active Abandoned
- 2004-03-05 BR BRPI0408113-7A patent/BRPI0408113A/pt not_active IP Right Cessation
- 2004-03-05 CN CN2004800118192A patent/CN1780616B/zh not_active Expired - Fee Related
- 2004-03-05 JP JP2006509174A patent/JP2006519875A/ja active Pending
- 2004-03-05 ZA ZA200507322A patent/ZA200507322B/en unknown
- 2004-03-05 NZ NZ542408A patent/NZ542408A/en unknown
- 2004-03-05 AU AU2004220607A patent/AU2004220607B2/en not_active Ceased
-
2005
- 2005-09-06 IL IL170710A patent/IL170710A0/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001348A2 (fr) * | 1993-07-02 | 1995-01-12 | Celgene Corporation | Inhibiteurs du tnf alpha |
WO1997008143A1 (fr) * | 1995-08-29 | 1997-03-06 | Celgene Corporation | Inhibiteurs du facteur de necrose des tumeurs alpha |
WO1999006041A1 (fr) * | 1997-07-31 | 1999-02-11 | Celgene Corporation | ACIDES ALCANOHYDROXAMIQUES SUBSTITUES ET PROCEDE PERMETTANT DE REDUIRE LE NIVEAU DE TNF-$g(a) |
WO2001034606A1 (fr) * | 1999-11-12 | 2001-05-17 | Celgene Corporation | Derives d'isoindoline actifs d'un point de vue pharmaceutique |
WO2001049321A1 (fr) * | 1999-12-31 | 2001-07-12 | Tobinick Edward L | Inhibiteurs du tnf destines au traitement de troubles neurologiques, retiniens et musculaires |
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
WO2003080048A1 (fr) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: leurs procedes d'utilisation et leurs compositions |
WO2005094218A2 (fr) * | 2004-03-05 | 2005-10-13 | Celgene Corporation | Procedes d'utilisation et compositions comprenant des medicaments selectifs inhibiteurs de cytokine pour le traitement et la gestion de troubles du systeme nerveux central |
Non-Patent Citations (2)
Title |
---|
MOGI M ET AL: "Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 165, no. 1-2, 3 January 1994 (1994-01-03), pages 208 - 210, XP024375768, ISSN: 0304-3940, [retrieved on 19940103] * |
SRIRAM KRISHNAN ET AL: "Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY SEP 2002, vol. 16, no. 11, September 2002 (2002-09-01), pages 1474 - 1476, XP002522289, ISSN: 1530-6860 * |
Also Published As
Publication number | Publication date |
---|---|
AU2004220607A1 (en) | 2004-09-23 |
AU2004220607B2 (en) | 2009-06-11 |
WO2004080393A3 (fr) | 2004-12-02 |
MXPA05009435A (es) | 2005-11-23 |
EP1605935A2 (fr) | 2005-12-21 |
KR100831545B1 (ko) | 2008-05-21 |
ZA200507322B (en) | 2007-03-28 |
BRPI0408113A (pt) | 2006-03-01 |
CN1780616B (zh) | 2010-05-12 |
IL170710A0 (en) | 2011-08-01 |
CN1780616A (zh) | 2006-05-31 |
CA2517845A1 (fr) | 2004-09-23 |
KR20050109971A (ko) | 2005-11-22 |
NZ542408A (en) | 2009-03-31 |
WO2004080393A2 (fr) | 2004-09-23 |
JP2006519875A (ja) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL175074A0 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatement, modification and management of pain | |
IL165258A0 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
EP1471909A4 (fr) | Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central | |
EP1755654A4 (fr) | Methodes et systemes de traitement d'affections neurologiques du systeme nerveux central | |
AU2003249983A8 (en) | Piperidines useful for the treatment of central nervous system disorders | |
EP1816990A4 (fr) | Systemes, dispositifs et procedes de traitement de troubles intervertebraux | |
IL177861A0 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | |
HK1152243A1 (en) | Vegf for use in the treatment of central nervous system disorders vegf | |
IL178142A0 (en) | Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders | |
AU2003286567A8 (en) | Methods for the treatment of skin disorders | |
IL170710A0 (en) | Selective cytokine inhibitory drugs for treating disorders of the central nervous system | |
EP1567154A4 (fr) | Procedes et compositions utilisant des medicaments d'inhibition selective de cytokine pour traiter et maitriser des cancers et d'autres maladies | |
HUP0501017A3 (en) | Methods and compositions for treatment of central nervous system disorders | |
EP1699431A4 (fr) | Compositions pour le traitement de troubles auriculaires et procedes d'utilisation de ces compositions | |
ZA200503241B (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
IL179038A0 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
IL176453A0 (en) | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases | |
EP1534295A4 (fr) | Formulations et methodes d'administration de cephalotaxines, dont homoharringtonine | |
AU2003300409A1 (en) | Word scramble games for stimulating brain and physical health | |
EP1569903A4 (fr) | Methodes d'utilisation d'agents inhibiteurs selectifs de la cytokine et compositions comprenant ces agents pour le traitement et la gestion de maladies myeloproliferatives | |
EP1744748A4 (fr) | Procedes d'utilisation et compositions comprenant des medicaments d'inhibition selective de cytokine, pour traiter et controler des syndromes myelodysplasiques | |
IL179040A0 (en) | Methods of using and compositions comrpising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases | |
PL376756A1 (pl) | Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych | |
EP1567148A4 (fr) | Methodes d'utilisation et compositions contenant des substances medicamenteuses d'inhibition selective des cytokines pour traiter et controler la degenerescence | |
EP1539100A4 (fr) | Compositions et methodes pour le traitement de troubles cutanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050929 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CELGENE CORPORATION |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090421 |
|
17Q | First examination report despatched |
Effective date: 20091014 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20101119 |